Published in N Engl J Med on October 11, 2007
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol (2009) 9.39
Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst (2009) 7.95
Preservation of fertility in patients with cancer. N Engl J Med (2009) 7.11
Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med (2008) 6.54
Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol (2010) 5.50
Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell (2009) 5.24
Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol (2009) 4.66
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA (2011) 4.63
Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res (2009) 4.02
Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol (2010) 2.91
Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. J Clin Oncol (2012) 2.85
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet (2009) 2.75
Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer (2009) 2.60
MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res (2009) 2.59
TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol (2012) 2.45
Clinicopathological features of tumors as predictors of the efficacy of primary neoadjuvant chemotherapy for operable breast cancer. World J Surg (2009) 2.02
Personalized medicine in oncology: the future is now. Nat Rev Drug Discov (2010) 1.91
TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. Lancet Oncol (2011) 1.85
Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer (2012) 1.75
Understanding and treating triple-negative breast cancer. Oncology (Williston Park) (2008) 1.73
Triple-negative breast cancer. Breast Cancer Res (2010) 1.65
Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol (2013) 1.62
Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer. Cancer Res (2008) 1.56
Triple-negative breast cancer: role of specific chemotherapy agents. Cancer J (2010) 1.51
Breast-cancer therapy--looking back to the future. N Engl J Med (2007) 1.51
Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology. Per Med (2010) 1.47
Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancer. Br J Cancer (2013) 1.46
Retracted An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer. PLoS One (2008) 1.45
Basal breast cancer: a complex and deadly molecular subtype. Curr Mol Med (2012) 1.43
Biomarkers in Breast Cancer - An Update. Geburtshilfe Frauenheilkd (2012) 1.41
An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. Ann Oncol (2010) 1.35
Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer. Nat Rev Clin Oncol (2009) 1.34
Recent advances in systemic therapy: new diagnostics and biological predictors of outcome in early breast cancer. Breast Cancer Res (2009) 1.28
Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study. Breast Cancer Res (2012) 1.26
Systemic treatment strategies for triple-negative breast cancer. World J Clin Oncol (2014) 1.25
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol (2016) 1.18
Risk assessment, disease prevention and personalised treatments in breast cancer: is clinically qualified integrative approach in the horizon? EPMA J (2013) 1.17
Simvastatin prevents skeletal metastasis of breast cancer by an antagonistic interplay between p53 and CD44. J Biol Chem (2011) 1.14
Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool. Br J Cancer (2010) 1.13
Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance. Clin Cancer Res (2009) 1.13
Clinical trials in the era of personalized oncology. CA Cancer J Clin (2011) 1.13
Qualitative age interactions in breast cancer studies: mind the gap. J Clin Oncol (2009) 1.12
Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel. PLoS One (2012) 1.12
PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer. Breast Cancer Res Treat (2013) 1.10
Recent advances in systemic therapy: advances in adjuvant systemic chemotherapy of early breast cancer. Breast Cancer Res (2009) 1.09
Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer. Breast Cancer Res (2013) 1.08
Treatment options for patients with triple-negative breast cancer. J Hematol Oncol (2010) 1.07
18F-fluorodeoxyglucose positron emission tomography optimizes neoadjuvant chemotherapy for primary breast cancer to achieve pathological complete response. Int J Clin Oncol (2011) 1.07
Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. Breast Cancer Res Treat (2011) 1.06
Multistage vectored siRNA targeting ataxia-telangiectasia mutated for breast cancer therapy. Small (2013) 1.05
Predictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapy. Br J Cancer (2010) 1.05
DNA repair gene patterns as prognostic and predictive factors in molecular breast cancer subtypes. Oncologist (2013) 1.04
Membranous expression of Her3 is associated with a decreased survival in head and neck squamous cell carcinoma. J Transl Med (2011) 1.04
Antitumor activity of phenethyl isothiocyanate in HER2-positive breast cancer models. BMC Med (2012) 1.03
Triple-negative breast cancer: adjuvant therapeutic options. Chemother Res Pract (2011) 1.03
GRP78 as potential predictor for breast cancer response to adjuvant taxane therapy. Int J Cancer (2011) 1.01
Triple-negative breast cancer: are we making headway at least? Ther Adv Med Oncol (2012) 1.01
Antiangiogenic agents significantly improve survival in tumor-bearing mice by increasing tolerance to chemotherapy-induced toxicity. Proc Natl Acad Sci U S A (2011) 1.01
Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. Br J Cancer (2008) 0.99
The prognostic value of BRCA1 promoter methylation in early stage triple negative breast cancer. J Cancer Ther Res (2014) 0.99
Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer. J Clin Oncol (2010) 0.96
The role of targeted therapy and biomarkers in breast cancer treatment. Clin Exp Metastasis (2012) 0.96
Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes? Ann Oncol (2012) 0.94
p53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905). Clin Cancer Res (2011) 0.94
Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence score. Oncologist (2011) 0.94
Myeloperoxidase genotypes and enhanced efficacy of chemotherapy for early-stage breast cancer in SWOG-8897. J Clin Oncol (2009) 0.92
TLE3 as a candidate biomarker of response to taxane therapy. Breast Cancer Res (2009) 0.92
Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome. Am J Pathol (2010) 0.92
Testing for HER2 in Breast Cancer: A Continuing Evolution. Patholog Res Int (2010) 0.92
Clinicopathological features and treatment strategy for triple-negative breast cancer. Int J Clin Oncol (2010) 0.92
Emerging trends in the treatment of triple-negative breast cancer in Canada: a survey. Curr Oncol (2011) 0.91
Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial. Breast Cancer Res (2011) 0.91
HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy. J Transl Med (2012) 0.89
Taxane benefit in breast cancer--a role for grade and chromosomal stability. Nat Rev Clin Oncol (2013) 0.89
Poor-prognosis estrogen receptor- positive disease: present and future clinical solutions. Ther Adv Med Oncol (2012) 0.89
DNA repair and personalized breast cancer therapy. Environ Mol Mutagen (2010) 0.88
Value of TP53 status for predicting response to neoadjuvant chemotherapy in breast cancer: a meta-analysis. PLoS One (2012) 0.88
Randomized adjuvant trials in oncology: a necessity or time-consuming luxury? Breast Cancer Res (2010) 0.88
Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes. J Cancer (2016) 0.87
Tamoxifen resistance in early breast cancer: statistical modelling of tissue markers to improve risk prediction. Br J Cancer (2010) 0.87
The role of taxanes in triple-negative breast cancer: literature review. Drug Des Devel Ther (2015) 0.86
Poly(2-oxazoline) based micelles with high capacity for 3rd generation taxoids: preparation, in vitro and in vivo evaluation. J Control Release (2015) 0.86
Tree-based methods for individualized treatment regimes. Biometrika (2015) 0.85
First efficacy results of capecitabine with anthracycline- and taxane-based adjuvant therapy in high-risk early breast cancer: a meta-analysis. PLoS One (2012) 0.85
Clinical implications of using molecular diagnostics for ovarian cancers. Ann Oncol (2013) 0.85
HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med (2008) 0.84
HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med (2008) 0.84
Therapeutic usefulness of postoperative adjuvant chemotherapy with Tegafur-Uracil (UFT) in patients with breast cancer: focus on the results of clinical studies in Japan. Oncologist (2010) 0.84
Can the status of the breast and ovarian cancer susceptibility gene 1 product (BRCA1) predict response to taxane-based cancer therapy? Anticancer Agents Med Chem (2009) 0.84
The screening mammography paradox: better when found, perhaps better not to find. Br J Cancer (2008) 0.83
A DNA repair BRCA1 estrogen receptor and targeted therapy in breast cancer. Int J Mol Sci (2012) 0.83
The epidermal growth factor receptor family in breast cancer. Onco Targets Ther (2008) 0.83
Non-invasive proteomics-thinking about personalized breast cancer screening and treatment. EPMA J (2010) 0.82
Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study. J Transl Med (2015) 0.81
Moving from correlative science to predictive oncology. EPMA J (2010) 0.81
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med (2005) 33.60
Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med (2004) 27.92
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA (2006) 24.01
Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol (2009) 22.22
International network of cancer genome projects. Nature (2010) 20.35
Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature (2010) 19.68
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol (2007) 14.29
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med (2003) 13.81
The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics (2006) 12.45
The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med (2007) 12.23
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst (2009) 10.91
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol (2003) 9.72
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol (2009) 9.39
Benefits and harms of CT screening for lung cancer: a systematic review. JAMA (2012) 8.71
American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol (2005) 8.56
Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med (2011) 8.19
Representational oligonucleotide microarray analysis: a high-resolution method to detect genome copy number variation. Genome Res (2003) 7.86
Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med (2002) 7.84
Epidemiology of basal-like breast cancer. Breast Cancer Res Treat (2007) 7.08
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol (2005) 6.90
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med (2014) 6.76
Tumor self-seeding by circulating cancer cells. Cell (2009) 6.66
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol (2004) 6.59
Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol (2013) 6.56
Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med (2008) 6.54
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA (2006) 6.45
American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol (2010) 6.39
Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med (2009) 5.68
Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol (2014) 5.61
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med (2015) 5.57
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst (2005) 5.55
Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol (2010) 5.50
Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell (2009) 5.24
Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med (2014) 5.18
Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol (2008) 5.10
Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA (2009) 5.05
Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol (2003) 4.95
Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res (2006) 4.95
A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell (2012) 4.89
Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med (2004) 4.84
Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol (2011) 4.81
Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. Proc Natl Acad Sci U S A (2008) 4.76
Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov (2012) 4.72
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res (2010) 4.61
Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med (2009) 4.60
HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol (2006) 4.55
Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med (2015) 4.53
Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol (2008) 4.45
Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol (2008) 4.42
CNS metastases in breast cancer. J Clin Oncol (2004) 4.42
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat (2006) 4.35
Novel patterns of genome rearrangement and their association with survival in breast cancer. Genome Res (2006) 4.25
Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol (2008) 4.24
Quality of non-breast cancer health maintenance among elderly breast cancer survivors. J Clin Oncol (2003) 4.24